Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

In patients with stable cardiovascular disease, those receiving rivaroxaban plus aspirin had fewer major cardiovascular events but more major bleeding events than those receiving aspirin alone. Rivaroxaban alone did not result in fewer major cardiovascular events than aspirin alone.

Uložené v:

Podrobná bibliografia
Vydané v:	The New England journal of medicine Ročník 377; číslo 14; s. 1319 - 1330
Hlavní autori:	Eikelboom, John W, Connolly, Stuart J, Bosch, Jackie, Dagenais, Gilles R, Hart, Robert G, Shestakovska, Olga, Diaz, Rafael, Alings, Marco, Lonn, Eva M, Anand, Sonia S, Widimsky, Petr, Hori, Masatsugu, Avezum, Alvaro, Piegas, Leopoldo S, Branch, Kelley R.H, Probstfield, Jeffrey, Bhatt, Deepak L, Zhu, Jun, Liang, Yan, Maggioni, Aldo P, Lopez-Jaramillo, Patricio, O’Donnell, Martin, Kakkar, Ajay K, Fox, Keith A.A, Parkhomenko, Alexander N, Ertl, Georg, Störk, Stefan, Keltai, Matyas, Ryden, Lars, Pogosova, Nana, Dans, Antonio L, Lanas, Fernando, Commerford, Patrick J, Torp-Pedersen, Christian, Guzik, Tomek J, Verhamme, Peter B, Vinereanu, Dragos, Kim, Jae-Hyung, Tonkin, Andrew M, Lewis, Basil S, Felix, Camilo, Yusoff, Khalid, Steg, P. Gabriel, Metsarinne, Kaj P, Cook Bruns, Nancy, Misselwitz, Frank, Chen, Edmond, Leong, Darryl, Yusuf, Salim
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Massachusetts Medical Society 05.10.2017
Predmet:	Aged Anticoagulants Arteriosclerosis Aspirin Aspirin - adverse effects Aspirin - therapeutic use Atherosclerosis Atherosclerosis - complications Atherosclerosis - drug therapy Bleeding Cardiovascular disease Cardiovascular Diseases - drug therapy Cardiovascular Diseases - mortality Cardiovascular Diseases - prevention & control Cerebral infarction Coronary vessels Disease prevention Double-Blind Method Drug dosages Drug therapy Drug Therapy, Combination Factor Xa Inhibitors - adverse effects Factor Xa Inhibitors - therapeutic use Female Hemorrhage - chemically induced Human health and pathology Humans Life Sciences Male Medical research Middle Aged Myocardial infarction Platelet Aggregation Inhibitors - adverse effects Platelet Aggregation Inhibitors - therapeutic use Rivaroxaban - adverse effects Rivaroxaban - therapeutic use Secondary Prevention - methods
ISSN:	0028-4793, 1533-4406, 1533-4406
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	In patients with stable cardiovascular disease, those receiving rivaroxaban plus aspirin had fewer major cardiovascular events but more major bleeding events than those receiving aspirin alone. Rivaroxaban alone did not result in fewer major cardiovascular events than aspirin alone.
Bibliografia:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa1709118